 |
|
Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions
A Systematic Review
Kathryn A. Phillips, PhD;
David L. Veenstra, PhD, PharmD;
Eyal Oren, BA;
Jane K. Lee, BA;
Wolfgang Sadee, PhD
JAMA. 2001;286:2270-2279.
ABSTRACT
| |
Context Adverse drug reactions are a significant cause of morbidity and mortality. Although many adverse drug reactions are considered nonpreventable, recent developments suggest these reactions may be avoided through individualization of drug therapies based on genetic information, an application known as pharmacogenomics.
Objective To evaluate the potential role of pharmacogenomics in reducing the incidence of adverse drug reactions.
Data Sources MEDLINE English-language only searches for adverse drug reaction studies published between January 1995 and June 2000 and review articles of variant alleles of drug-metabolizing enzymes published between January 1997 and August 2000. We also used online resources, texts, and expert opinion.
Study Selection Detailed inclusion criteria were used to select studies. We included 18 of 333 adverse drug reaction studies and 22 of 61 variant allele review articles.
Data Extraction All the investigators reviewed and coded articles using standardized abstracting forms.
Data Synthesis We identified 27 drugs frequently cited in adverse drug reaction studies. Among these drugs, 59% are metabolized by at least 1 enzyme with a variant allele known to cause poor metabolism. Conversely, only 7% to 22% of randomly selected drugs are known to be metabolized by enzymes with this genetic variability (range, P = .006-P<.001).
Conclusions Our results suggest that drug therapy based on individuals' genetic makeups may result in a clinically important reduction in adverse outcomes. Our findings serve as a foundation for further research on how pharmacogenomics can reduce the incidence of adverse reactions and on the resulting clinical, societal, and economic implications.
INTRODUCTION
Several highly publicized reports and policy initiatives have urged greater efforts to reduce the rate of adverse events in medical care.1-4 Pharmaceutical agents are one of the most commonly identified causes of adverse events, resulting in significant patient morbidity, mortality, and excess medical care costs.2, 5 A widely cited meta-analysis estimated that more than 2 million hospitalized patients have severe adverse drug reactions (ADRs) annually in the United States even when drugs are appropriately prescribed and administered, and that ADRs ranked between the fourth and sixth leading cause of death in the United States in 1994.6 However, there have not been any updated, systematic reviews published since that time.
One possible cause of ADRs is genetic variation in how individuals metabolize drugs. The Human Genome Project heralds new opportunities for using genetic information to individualize drug therapy, called pharmacogenomics.7 In fact, pharmacogenomics may be one of the most immediate clinical applications of the Human Genome Project8 and may become part of standard practice for "quite a number of disorders and drugs by year 2020."9
A primary benefit of pharmacogenomics that has been repeatedly cited in prominent articles is the potential to reduce ADRs.10-15 Some ADRs caused by genetic variation—previously considered nonpreventable—may now be preventable. Adverse drug reactions could be reduced by modifying drug selection or dosing in patients with poor ability to metabolize a drug because of genetic variation in their drug metabolizing enzymes or by developing drugs a priori that will avoid metabolic pathways with adverse genetic variability.
Despite the commonly accepted notion that pharmacogenomics will reduce ADRs, there have not been any systematic and quantitative evaluations of the potential role of genetic variability in ADRs. Typically, studies have addressed either the nongenetic causes of adverse events such as human error2, 5 or specific genetic variants associated with drug metabolizing enzymes without linking this to the ADR literature.14, 16-17 Although several studies have found a direct link between specific genetic variants and ADRs,18-19 these are single studies that have not been systematically combined.
The purpose of this study was to evaluate the potential role of pharmacogenomics in reducing the incidence of ADRs and to discuss the clinical and policy implications. Specifically, we conducted 2 systematic literature reviews: one for studies reporting ADRs and the other for studies reporting variant alleles of drug-metabolizing enzymes. The results of the 2 reviews were then "linked" via the enzymes responsible for metabolizing each of the drugs to examine the possible contribution of genetic variability to ADRs.
This is the first study to our knowledge to systematically identify which specific drugs are linked to ADRs and the genetic variability in drug-metabolizing enzymes relevant to those drugs and to evaluate these findings in a clinical and policy context.
METHODS
Scope of Study and Definitions
We restricted the scope of our analysis as shown in Figure 1. Within the adverse drug event literature, we focused on ADRs. We used the common definition of ADRs as any noxious, unintended, and undesired effect of a drug that occurs at doses used in humans for prophylaxis, diagnosis, or therapy, excluding therapeutic failures, intentional overdose, errors in drug administration, and noncompliance.6 Adverse drug reactions are caused by inherent properties of drugs (and are thus often called nonpreventable); therefore, they have the most relevance to our study. In contrast, adverse drug events (ADEs) include preventable events, such as human errors. We focused on drug-metabolizing enzymes, rather than receptors or transporters, since drug-metabolizing enzymes are the predominantly known cause of genetic variability in drug response. We examined both phase 1 and phase 2 drug-metabolizing enzymes. Phase 1 drug-metabolizing enzymes are composed mainly of P450 cytochromes (CYPs) that oxidize drugs while phase 2 enzymes conjugate drugs for subsequent excretion. Genetic variants of phase 1 drug-metabolizing enzymes have been extensively studied whereas existing data on phase 2 drug-metabolizing enzymes are less comprehensive.
Within the genetics and genomics literature, we focused on pharmacogenomics. Although both pharmacogenetics and the broader field of pharmacogenomics address genetic factors responsible for variation in drug response among patients, we use the term pharmacogenomics in this article. For each gene encoding a drug-metabolizing enzyme, variant alleles may exist (called polymorphisms when they occur in more than 1% of the population). Our primary analysis focuses only on drug-metabolizing enzymes with known variant alleles that cause poor metabolism because these are most relevant to ADRs.
Lastly, we linked our 2 literature reviews. Thus, the scope of our study is limited to drug-metabolizing enzymes with known variant alleles causing poor metabolism of drugs frequently identified in ADR studies.
Below we discuss the literature review of ADRs, the literature review of variant alleles and how these were linked. Each review is treated as a separate study due to its complex nature, and details are provided in an online appendix (available in PDF format: ).
We conducted pilot studies to assess the study's feasibility and to refine our methods (details are available on request). All inclusion and coding decisions were documented in standardized spreadsheets. Two reviewers (E.O., J.L.) conducted the majority of coding, while others (K.P., D.V., W.S.) reviewed the results and reconciled differences.
We synthesized the literature by applying the same systematic approaches used in meta-analysis.20 However, we did not estimate summary effect sizes. As several studies have noted, it is difficult to estimate accurately the true incidence of ADRs—and even more difficult to estimate incidence based on specific drugs—because of heterogeneity among studies.1-2,21 It is also currently not feasible to estimate a summary measure of attributable impact.
Methods for Determining Drugs Identified in ADR Studies
Literature Search. Previous systematic ADR reviews have used keyword searches,6 but we found in pilot studies that a keyword search would have low sensitivity and specificity. We thus developed a specific MEDLINE search strategy using Medical Subject Headings (MeSH) terms, using 19 articles previously identified as key articles2, 6 (available on request). We included studies from the past 5 years (January 1995-June 2000) to extend a previous meta-analysis.6 Our search strategy, resulting in 333 hits, was major exact subject drug therapy-adverse effects or pharmaceutical preparations-adverse effects or medication errors-statistics and numerical data or iatrogenic disease-epidemiology and language English and exact subject human and publication type journal article and not review.
Article Selection. Inclusion criteria were studies that
- reported ADRs (single or multidrug) or ADRs in combination with ADEs,
- included information on drug classes, specific drugs, or both involved in ADRs,
- examined actual ADRs in clinical practice settings,
- were US based (to create a more homogeneous sample),
- and reported original data.
We excluded studies reporting only on ADEs, hypothesized ADRs, clinical trials of specific drugs, reviews, case reports, and articles with redundant data. We tested the impact of our inclusion criteria on our results by conducting sensitivity analyses based on key study characteristics (online appendix [available in PDF format: ]).
We excluded 206 studies based on the abstract for a total of 127 potentially eligible studies. Review of full articles' text resulted in a final total of 18 studies.22-39 In each screening phase, about one third of excluded studies were conducted outside the United States, one third did not include ADRs, and one fourth were not primary data.
Article Coding. We coded each study for the specific drugs identified. We used the Drug Information Handbook40 to add class and therapeutic category information. We included drug-drug interactions in our database because of evidence that such interactions may be due to genetic variability. Since the classification of drug-drug interactions as avoidable ADEs or unavoidable ADRs was inconsistent in the literature, we could not delineate those that might be true ADEs (and thus not caused by genetic variability). When a combination of specific drugs was named as causing an ADR, we coded each drug separately but counted it as a single observation.
Methods for Obtaining Data on Variant Alleles
Literature Search. We used the same approach in developing a search strategy as for the ADR articles, using 8 well-known articles as key studies (available on request). The period January 1997-August 2000 was chosen because articles from 1997 onward should capture recently identified variant alleles. We only included review articles because they were most relevant to our study and because of redundancy among the large numbers of original reports. We supplemented the review articles with data from an extensive Web site (http://www.imm.ki.se/CYPalleles).
Our search strategy was major exact subject cytochrome P-450—genetics or Pharmaceutical Preparations—metabolism or sulfotransferases—genetics or glutathione transferase—genetics or methyltransferases—genetics or glucuronosyltransferase—genetics or epoxide hydrolases—genetics or arylamine N-acetyltransferase—genetics and exact subject polymorphism genetics and language English and publication type review.
Article Selection. Articles that reviewed variant alleles of drug-metabolizing enzymes and their effect on drug metabolism were included. We excluded articles on gene-environment interaction (ecogenetics or disease risk), methods or techniques for genotyping, and editorials (39 studies were excluded; available on request). Based on reviews of article texts, 22 articles were included.13, 17, 41-59 Fifty-five percent of the exclusions were because the articles were not review articles.
Web Sources. The literature on variant alleles is rapidly growing and thus publications are often outdated and difficult to summarize because of differences in nomenclature. Therefore, we combined the literature review with data from the Human Cytochrome P450 (CYP) Allele Nomenclature Committee60 Web site (available at: http://www.imm.ki.se/CYPalleles, accessed January 2001). This Web site provides more valid data than a typical single site because it is a synthesis of prior work and is authored by an international committee. It is thought to be used by the majority of researchers in this area (M. Ingelman-Sundberg, written communication, January 17, 2001).
Article and Web site Coding. We coded the following information:
- enzyme family (eg, CYP2C9),
- variant alleles using standardized nomenclature (ie, specific alleles, eg, CYP2C9*2) and their functional effect (ie, whether known to be associated with poor metabolism),
- prevalence of individuals with poor metabolism (ie, decreased or no metabolism),
- prevalence of variant alleles.
Because prevalence data come from multiple and varying sources, we report ranges rather than point estimates.
Individuals possess 2 alleles for each gene encoding a drug-metabolizing enzymes and variations may occur in neither, one, or both alleles. Patients who are poor metabolizers are usually homozygous carriers of 2 nonfunctional alleles whereas heterozygotes are more frequent but often show only moderate impairment of metabolism. Some studies report data on the percentage of individuals who are poor metabolizers while others report the frequency of the variant alleles themselves in a population. We abstracted both types of data from the studies whenever possible.
Methods for Linking Drugs Identified in ADR Studies to Variant Alleles
Data on ADR-associated drugs and variant alleles were linked via the relevant enzymes (Figure 1). We expected that drugs identified in ADR studies would be more likely to be metabolized by enzymes with evidence of genetic variability than drugs not identified in ADR studies. We constructed 2 comparison groups to assess how likely these results occurred by chance by using a random sample of 27 drugs from all drugs sold in the United States61 and by using a random sample of 27 drugs from the top 200-selling drugs in the United States.62 In both samples, we excluded drugs found in the ADR literature review.
We also conducted 2 sensitivity analyses. First, to examine the implications of restricting our sample to the most cited drugs, we compared our results with those reported in a recent review of the ADE literature.2 Second, because our primary results are based on the top 27 drugs causing ADRs drawn from a list of 131 drugs, we conducted a reliability test by examining whether we obtained similar results using a random sample of 27 drugs drawn from the same list of drugs cited in ADR studies.
To identify drug-metabolizing enzymes involved in the metabolism of drugs cited in the ADR studies, we used multiple standard drug information sources40, 61, 63-64 as well as an online source (http://gentest.com) and drug interaction database.65 We also conducted MEDLINE searches for each included enzyme using MeSH, the name of the drug, and the word metabolism.
It is important to note that our coding was based on data as reported in the sources reviewed. Therefore, our estimates of the involvement of genetic factors in ADRs are probably conservative because new studies are rapidly finding new genetic variants. For example, enzymes CYP3A4 and CYP3A5 were not identified in the review articles as having nonfunctional variant alleles although recent studies have identified such alleles.66-67
RESULTS
ADR Literature Review
The majority of the ADR studies had patient sample sizes of less than 1000 and were based on hospital data, used nonprospective study designs, and included both ADRs and ADEs (online appendix [available in PDF format: ]). These studies identified 131 specific drugs, 55 drug classes, and 19 therapeutic drug categories as being associated with ADRs (online appendix [available in PDF format: ]). We restricted our primary analyses to drugs identified in 2 or more studies to avoid including isolated incidents (n = 27; Table 1). All except 3 of the included drugs are among the top 200 selling drugs in the United States,62 and therefore reducing ADRs from these drugs could have a relatively large impact.
|
|
|
|
Table 1. Commonly Identified Drugs in Adverse Drug Reaction Studies
|
|
|
Variant Alleles Literature Review
About half of these articles were published recently (1999-2000) and focused only on phase 1 P450 enzymes (online appendix [available in PDF format: ]). The reviews, in conjunction with the Web resources, identified a total of 25 enzymes and approximately 250 variant alleles.
Table 2 lists the enzymes, specific variant alleles, and prevalence of poor metabolizers and variant alleles relevant to the drugs we found in the ADR studies. This table only includes enzymes for ADR-associated drugs and it is limited to variant alleles known to cause poor metabolism (Table 3; online appendix [available in PDF format: ]). Although the 6 phase 1 enzymes listed on Table 2 represent only one third of all phase 1 enzymes identified by our literature review, they represent 86% of the total phase 1 enzymes identified as having variant alleles known to cause poor metabolism.
|
|
|
|
Table 2. Variant Alleles With Known Poor Metabolism for Enzymes That Metabolize Adverse Drug Reaction-Implicated Drugs*
|
|
|
|
|
|
|
Table 3. Drugs Implicated in Adverse Drug Reactions (ADRs) Metabolized by Enzymes With Variant Alleles Associated With Poor Metabolism*
|
|
|
The prevalence of poor metabolizers and variant alleles shows substantial variability across and within enzymes (Table 2). For example, the NAT2 enzyme shows wide variability of poor metabolizers across racial and ethnic groups (Japanese, 8%-10%; white, 50%-59%; Egyptian, 92%), and some Asian groups show higher prevalence of poor metabolism and/or variant alleles in the CYP2C18, CYP2C19, and CYP2D6 families. Therefore, these groups may be more susceptible to ADRs from drugs metabolized by those enzymes. However, there are many gaps in the available prevalence data.
Primary Results
Linking Drugs Identified in ADR Studies to Variant Alleles. We found that 59% (16/27) of the drugs cited in the ADR studies are metabolized by at least 1 enzyme with a variant allele known to cause poor metabolism. Conversely, only 22% of randomly selected drugs sold in the United States (P = .006, z test) and 7% of randomly selected top-selling US drugs are metabolized by enzymes with this genetic variability (P<.001, z test). Although our study design does not allow for causal inferences, these analyses support the hypothesis that drugs identified in ADR studies would be more likely to be metabolized by enzymes with genetic variability than drugs not identified in ADR studies.
The results for enzymes CYP1A2 and CYP2D6 are particularly interesting (Table 2 and Table 3). The CYP1A2 enzyme has only 1 identified variant allele with poor metabolism, but there is a significant prevalence of poor metabolizers of CYP1A2 substrates among whites. Whereas CYP1A2 is estimated to be the major metabolic pathway for only 5% of all prescribed drugs,68 it is involved (at least partly) in metabolizing 75% of the ADR drugs associated with variant alleles. Although CYP1A2 is only a minor enzyme for many of these drugs, these results indicate that CYP1A2 might play a more important role in ADRs than previously identified and therefore an area into which further research may be useful. On the other hand, CYP2D6 is estimated to be the major metabolic pathway for 25% of all prescribed drugs68 and is widely suspected of causing ADRs because it has a multitude of known variant alleles. However, CYP2D6 has a slightly lower prevalence of poor metabolizers (3%-10% whites) than CYP1A2. Moreover, we found CYP2D6 to be involved in metabolizing 38% of the relevant ADR drugs. Although this incidence is greater than among randomly selected drugs, it is less than what is observed for CYP1A2. These results may reflect an increasing awareness of CYP2D6 variants as a complicating factor in drug therapy and the selection of non-2D6 drugs if severe adverse effects are likely.69
Sensitivity Analyses
First, our sample appears to be generally representative of reported ADRs. The top 4 most frequently occurring drug categories in our study, accounting for 61% of observations, were cardiovascular, antibiotics, psychiatric, and analgesic. These are the also the most frequent categories reported in the General Accounting Office review.2 (Note that there was no available comparison of specific drugs rather than drug categories.)
Second, our results appear to be reliable; that is, we would have obtained the same results if we had chosen another group of drugs from the drugs found in our ADR literature review. Using a sample of randomly selected drugs cited in the ADR studies, we found that 44% are metabolized by at least 1 enzyme with a variant allele known to cause poor metabolism—a proportion that is not significantly different from our results using the most frequently cited drugs in the ADR studies (95% confidence interval [CI], 27%-61% using a finite population correction to adjust the sample variance). These findings suggest that our results are not biased by focusing only on the 27 most frequently cited drugs.
COMMENT
We found that more than half of the drugs cited in ADR studies are metabolized by at least 1 enzyme with a variant allele known to cause poor metabolism. These results suggest that genetic variability in drug metabolizing enzymes is likely to be an important contributor to the incidence of ADRs.
Many recent articles have noted the potential for a decrease in ADRs through the use of pharmacogenomics, but our study differs in several ways from previous work. First, we used a systematic approach to identify drugs associated with ADRs. Second, we conducted a systematic review of variant alleles of drug-metabolizing enzymes. Third, we linked these data sets to assess the potential contribution of genetic variability to ADRs. However, the link between ADRs and genetic variability is complex, and our findings do not imply a causal relationship or that ADR incidence would necessarily be reduced if drug selection and dosing were based on genetic variability. Our findings do indicate, however, that the converse hypothesis—there is no relationship between ADRs and genetic variants—is probably not true, and our findings suggest in what area future research may have the greatest pay-off.
Clinical, Industrial, and Societal Perspectives
The application of pharmacogenomics information has great potential but also faces substantial challenges. We summarize herein some of the key issues from a clinical, industrial, and societal perspective. We then provide a clinician's checklist and discuss criteria that can be used to evaluate the potential impact of pharmacogenomics information in reducing ADRs.70-71
From a clinical perspective, there are obvious potential benefits to individualized drug therapy although there are many issues that must first be addressed.69, 72-73 Currently, clinical applications, although beginning to emerge, lag behind the available technology. For example, a clinical test for the CYP2D6 enzyme has been developed and may be available in physicians' offices within the next 2 years.74 However, currently, genotyping for enzymes is used only in a limited number of primarily academic centers, eg, genotyping for the CYP2D6 enzyme to aid individual dose selection for drugs to treat psychiatric illness,10 genotyping for thiopurine methyltransferase (TPMT) for treatments for childhood leukemia,75 and HER-2 receptor expression levels for herceptin breast cancer therapy.76 A relatively more common use of genotyping is for viruses instead of individuals, eg, genotyping of the human immunodeficiency virus.70, 77 Others have noted particularly important uses of genotyping for the near future, for treatment for such diseases as Alzheimer disease, atherosclerosis, and cerebral-vein thrombosis among women who have taken oral contraceptives.7
In general, however, clinical practice is not yet prepared to benefit from the genetics revolution. Most health care professionals have not had "even one hour" of instruction in pharmacogenomics as part of their formal training.78 Therefore, moving pharmacogenomics from bench to bedside will be a challenging undertaking.
From an industry perspective, there will be both pros and cons to developing drugs a priori that will avoid ADRs. On the one hand, drug development may become more efficient and less costly as a result of the use of genetic information.69, 79-80 Pharmacogenomics may also allow companies to resurrect drugs that have failed clinical trials by using genetic information to target them to a smaller group than the population. However, small-target populations may also decrease incentives for companies to develop new drugs and present other challenges, such as recruitment into trials.
From a societal perspective, we have only begun to examine the social, economic, and ethical aspects of pharmacogenomics.70, 81-84 Research to date has focused more on the use of genetic information to predict future risk, such as privacy issues involved in testing for the BRCA gene to determine risk for breast cancer,7 than on individualized drug therapy. Only a few studies have begun to address the economic impact of introducing genotyping as a guide for developing individual therapy85: whether it should be provided and to whom, how much it would cost,44 and whether insurers would cover it.86 It will thus be critical to conduct cost-effectiveness analyses and other evaluations of the clinical, economic, and societal effect of pharmacogenomics. For example, race is correlated with many gene patterns and therefore genotyping raises issues about stereotyping and preferential treatment.8, 73 As stated by one observer, "What happens when the patient comes in and says, ‘I hear there's a great new drug for asthma,' and the doctor says, ‘Yeah, but it's only for whites?'"8
Evaluating the Potential Impact of Pharmacogenomics Information in Reducing ADRs
Even when metabolism of a drug is found to have genetic variability, the ultimate question is: "Does it matter?" It is currently difficult to estimate the attributable impact of genetic variability on ADRs because this would require complex data on many factors that are unknown. However, we have outlined criteria that can be used to evaluate the potential impact of pharmacogenomics information in reducing ADRs from a clinical and societal perspective. These criteria can guide future research, assist clinicians in considering these issues, and serve as starting points for more comprehensive analyses of the cost-effectiveness and cost-benefits of pharmacogenomic information.
The potential effect of pharmacogenomics information from a societal perspective will be a function of medical need, clinical utility, and ease of use (BOX 1). Medical need will be driven primarily by the prevalence of variant alleles in a population, the use of a drug in that population, the severity of the ADR, and the ability to monitor drug toxicity using current technologies. Genetic testing will be clinically appropriate only if there is sufficient evidence to link variant alleles with valid surrogate markers of drug toxicity or patient outcomes. And finally, genetic tests must be easy to use, and clinicians must be able to interpret them in order to gain widespread acceptance.
| Box 1. Criteria to Evaluate the Potential Impact of Pharmacogenomics Information in Reducing Adverse Drug Reactions (ADRs)
MEDICAL NEED
Prevalence of ADRs Caused by Drug
The incidence of ADRs and the use of a drug is high enough to warrant use of genetic information.
Prevalence of Poor Metabolizers and Variant Alleles
The prevalence of poor metabolizers and/or variant alleles is high enough to warrant use of genetic information. Depending on the clinical consequences of genetic variation, even a low prevalence may warrant genetically based interventions.
Outcome
The consequences of associated ADRs are severe enough to produce significant changes in clinical or quality of life end points, or lead to significant economic costs.
Monitoring
Current methods for monitoring therapeutic response or evaluating toxic effects are unavailable or inefficient.
CLINICAL UTILITY
Association
Sufficient evidence exists to link the variant allele to clinical response to a drug, and ultimately, patient outcomes (gene penetrance). Moreover, the genotyping assay is predictive for a substantial portion of the patient population, taking into account the most prevalent variant alleles contributing to the disease.
EASE OF USE
Assay
An assay that can rapidly, relatively inexpensively, and reliably detect the variant allele is available.
Clinicians
Clinicians are able to interpret the results and appropriately use the information.
Data are based on Spear,87 Phillips et al,70 and Veenstra et al.71
RETURN TO TEXT |
|
Although much of the information needed to apply pharmacogenomics information to clinical practice is currently unknown, our results do suggest several steps that clinicians can take when prescribing a drug with a high incidence of ADRs (BOX 2).
| Box 2. A Clinician's Checklist for Evaluating the Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions (ADRs)
Check whether the drug is known to be metabolized by a polymorphic drug-metabolizing enzyme. Pay special attention to the prevalence of polymorphic alleles of the relevant drug-metabolizing enzyme in the patient population being treated since prevalence varies considerably among groups.
If genetic variability may be a significant problem:
- Consider alternative drugs that may not be subject to known polymorphic drug-metabolizing enzymes.
- Advise the patient to carefully monitor adverse effects early in therapy.
- Be aware of compounded ADR problems when prescribing 2 or more drugs concomitantly that interact with the same drug-metabolizing enzymes.
- In some circumstances (particularly when a patient has an ADR and no alternative medication is available), genotyping can be considered to ascertain that a defective drug-metabolizing enzyme is the likely cause for the observed ADR and to permit an appropriate dosage reduction.
RETURN TO TEXT |
|
Example of Warfarin
We highlight the criteria in BOX 1 and BOX 2 by applying them to warfarin sodium, a drug commonly identified in ADR studies. Warfarin is an anticoagulant used in the prophylaxis and treatment of thromboembolic disorders and is metabolized primarily by the CYP2C9 enzyme. Individuals who are deficient in CYP2C9 enzyme activity may require a lower warfarin dose or more frequent monitoring and may be at higher risk for bleeding episodes.
Based on the high incidence of ADRs caused by warfarin, as demonstrated in our study and others,2, 88-89 the potential effect of interventions to reduce ADRs from warfarin could be high because of the high usage of warfarin, which ranks 29th in US drug sales62; the relatively high prevalence of poor metabolizers; and the severity of outcomes. The CYP2C9 enzyme genotype assays are readily performed at the clinical research level and are being developed for commercial use,13 and it is likely that clinicians would be able to interpret the results of such information. However, although several studies have found an association between the CYP2C9 genotype and ADRs, there has not been a definitive study linking CYP2C9 genotype to ADRs and warfarin dose requirements.90-91
Therefore, the assessment of warfarin using our criteria suggests that it provides an example of at what point pharmacogenomics information could reduce ADRs, but what is unknown is whether it actually will. Given that warfarin therapy is already individualized by assessing blood coagulation times and that the link between variant alleles and clinical outcomes is uncertain, it remains to be determined whether genotyping of warfarin patients would produce substantial additional gains.
Limitations
Our analysis should be considered only a first step in examining the association between genetic variability and ADRs. Most drugs have complex metabolic pathways so that multiple variant alleles could be responsible for ADRs. Furthermore, although most drug-metabolizing enzymes exhibit variant alleles, only some of these have been associated with changes in drug effects or adverse effects. Adverse drug reactions may also be a function of variant alleles at independently segregating loci and of environmental exposures. However, our study suggests what types of future studies of these associations may be fruitful. Our study is also limited because much of the data on which it is based are incomplete or of limited quality, and by necessity such a study requires some subjective decisions. Specifically, we were unable to derive quantitative summary estimates of ADR incidence and therefore our estimate of the most common drugs is relatively crude. Also, the review articles did not include recently discovered genetic variants or drugs that are less commonly used (eg, oncology drugs or immunosuppressives). However, we supplemented the review articles with data from an extensive Web site to improve the validity of our data. Finally, our comparisons of ADR-associated drugs to randomly selected drugs might be confounded by several factors. However, our results would have had to be dramatically different to change our primary conclusions, and sensitivity analyses suggest that our conclusions are robust.
Conclusion
The emergence of pharmacogenomics may herald a new era of individualized therapy. Hence, nonpreventable ADRs may become at least in part preventable, as a first step in optimizing drug therapy with genetic information. This study provides empirical evidence that the use of pharmacogenomics could potentially reduce ADRs, a problem of major significance. Our study illustrates the adage, "the sum can be greater than its parts": how 2 bodies of literature can produce additional insights when combined, and our study provides a foundation for future research.
In the future, we may all carry a "gene chip assay report" that contains our unique genetic profile that would be consulted before drugs are prescribed. However, the application of pharmacogenomics information faces significant challenges, and further basic science, clinical, and policy research is needed to determine in what areas pharmacogenomics can have the greatest impact, how it can be incorporated into practice, and what are its societal implications.
AUTHOR INFORMATION
Author Contributions: Study concept and design: Phillips, Veenstra, Sadee.
Acquisition of data: Phillips, Veenstra, Sadee.
Analysis and interpretation of data: Phillips, Veenstra, Oren, Lee, Sadee.
Drafting of the manuscript: Phillips, Veenstra, Sadee.
Critical revision of the manuscript for important intellectual content: Phillips, Veenstra, Oren, Lee, Sadee.
Statistical expertise: Phillips, Veenstra.
Obtained funding: Phillips.
Administrative, technical, or material support: Phillips, Oren, Lee.
Study supervision: Phillips,Veenstra.
Funding/Support: This study was supported in part by grants R01#AI43744 and NCI R01#CA81130 from the National Institute of Allergy and Infectious Diseases (Dr Phillips) and R01#CA81130 from the National Cancer Institute (Dr Phillips).
Acknowledgment: We thank Gary McCart, PharmD, and Eddie Lin, BS, of the University of California, San Francisco, and Joanna Huang, PharmD, Scott Ramsey, MD, PhD, and Ken Thummel, PhD, of University of Washington, and the participants in the Institute for Health Policy Studies Writing Seminar.
Corresponding Author and Reprints: Kathryn A. Phillips, PhD, School of Pharmacy, Institute for Health Policy Studies, and Center for AIDS Prevention Studies, University of California, San Francisco, 3333 California St, Room 420, Box 0613, San Francisco, CA 94143 (e-mail: kathryn{at}itsa.ucsf.edu).
Author Affiliations: Department of Clinical Pharmacy (Drs Phillips, Mr Oren, and Ms Lee) and Biopharmaceutics (Dr Sadee) University of California-San Francisco; Department of Pharmacy, University of Washington, Seattle (Dr Veenstra).
REFERENCES
| |
1. Kohn L, ed, Corrigan J, ed, Donaldson M, ed. To Err Is Human: Building a Safer Health System. Washington, DC: Institute of Medicine; 2000.
2. Adverse Drug Events: The Magnitude of Health Risk Is Uncertain Because of Limited Incidence Data. Washington, DC: US General Accounting Office; 2000.
3. Agency for Healthcare Research and Quality. Translating Research Into Practice: Reducing Errors in Health Care. Washington, DC: Agency for Healthcare and Research and Quality; 2000. AHRQ publication 00-PO58 ed.
4. Leape L, Berwick D. Safe health care: are we up to it? BMJ. 2000;320:725-726.
FREE FULL TEXT
5. Bates D, Gawande A. Error in medicine: what have we learned? Ann Intern Med. 2000;132:763-767.
FREE FULL TEXT
6. Lazarou J, Pomeranz B, Corey P. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200-1205.
FREE FULL TEXT
7. Collins F. Shattuck lecture: medical and societal consequences of the human genome project. N Engl J Med. 1999;341:28-37.
FREE FULL TEXT
8. Weiss R. The promise of precision prescriptions. Washington Post. June 24, 2000:A1. Available at: http://www.washingtonpost.com. Accessibility verified October 10, 2001.
9. Collins F, McKusick V. Implications of the Human Genome Project for Medical Science. JAMA. 2001;285:540-544.
FREE FULL TEXT
10. Wolf C, Smith G, Smith R. Pharmacogenetics. BMJ. 2000;320:987-990.
FREE FULL TEXT
11. Roses A. Pharmacogenetics and future drug development and delivery. Lancet. 2000;355:1358-1361.
FULL TEXT
|
ISI
| PUBMED
12. Weinstein JN. Pharmacogenomics: teaching old drugs new tricks. N Engl J Med. 2000;343:1408-1409.
FREE FULL TEXT
13. Evans W, Relling M. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487-491.
FREE FULL TEXT
14. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet. 2000;356:1667-1671.
FULL TEXT
|
ISI
| PUBMED
15. March R. Pharmacogenomics: the genomics of drug response. Yeast. 2000;17:16-21.
FULL TEXT
|
ISI
| PUBMED
16. Wormhoudt L, Commandeur J, Vermeulen N. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol. 1999;29:59-124.
FULL TEXT
|
ISI
| PUBMED
17. Coutts RT, Urichuk LJ. Polymorphic cytochromes P450 and drugs used in psychiatry. Cell Mol Neurobiol. 1999;19:325-354.
FULL TEXT
|
ISI
| PUBMED
18. Kapitany T, Meszaros K, Lenzinger E, et al. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res. 1998;32:101-106.
FULL TEXT
|
ISI
| PUBMED
19. Basile VS, Ozdemir V, Masellis M, et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry. 2000;5:410-417.
FULL TEXT
|
ISI
| PUBMED
20. Petitti D. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. New York, NY: Oxford University Press; 1994.
21. Kvasz M, Allen IE, Gordon MJ, et al. Adverse drug reactions in hospitalized patients: a critique of a meta-analysis. MedGenMed. 2000;:E3.
22. Aparasu R. Drug-related-injury visits to hospital emergency departments. Am J Health Syst Pharm. 1998;55:1158-1161.
FREE FULL TEXT
23. Aparasu R. Visits to office-based physicians in the United States for medication-related morbidity. J Am Pharm Assoc (Wash). 1999;39:332-337.
PUBMED
24. Bates D, Cullen D, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA. 1995;274:29-34.
FREE FULL TEXT
25. Buechner J. Adverse drug reactions in hospital patients. Med Health R I. 1998;81:60-61.
PUBMED
26. Classen D, Pestotnik S, Evans R, Lloyd J, Burke J. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277:301-306.
FREE FULL TEXT
27. Cooper J. Probable adverse drug reactions in a rural geriatric nursing home population: a four-year study. J Am Geriatr Soc. 1996;44:194-197.
ISI
| PUBMED
28. Gray S, Sager M, Lestico M, Jalaluddin M. Adverse drug events in hospitalized elderly. J Gerontol A Biol Sci Med Sci. 1998;53:M59-M63.
29. Gray S, Mahoney J, Blough D. Adverse drug events in elderly patients receiving home health services following hospital discharge. Ann Pharmacother. 1999;33:1147-1153.
ABSTRACT
30. Hamilton R, Briceland L, Andritz M. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacotherapy. 1998;18:1112-1120.
ISI
| PUBMED
31. Hanlon J, Schmader K, Koronkowski M, et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc. 1997;45:945-948.
ISI
| PUBMED
32. Johnstone D, Kirking D, Vinson B. Comparison of adverse drug reactions detected by pharmacy and medical records departments. Am J Health Syst Pharm. 1995;52:297-301.
ABSTRACT
33. Nelson K, Talbert R. Drug-related hospital admissions. Pharmacotherapy. 1996;16:701-707.
ISI
| PUBMED
34. Schneitman-McIntire O, Farnen T, Gordon N, Chan J, Toy W. Medication misadventures resulting in emergency department visits at HMO medical centers. Am J Health Syst Pharm. 1996;53:1416-1422.
ABSTRACT
35. Seeger J, Kong S, Schumock G. Characteristics associated with ability to prevent adverse drug reactions in hospitalized patients. Pharmacotherapy. 1998;18:1284-1289.
ISI
| PUBMED
36. Smith K, McAdams J, Frenia M, Todd M. Drug-related problems in emergency department patients. Am J Health Syst Pharm. 1997;54:295-298.
FREE FULL TEXT
37. Tafreshi M, Melby M, Kaback K, Nord T. Medication-related visits to the emergency department: a prospective study. Ann Pharmacother. 1999;33:1252-1257.
ABSTRACT
38. Thomas E, Studdert DM, Burstin HR, et al. Incidence and types of adverse events and negligent care in Utah and Colorado. Med Care. 2000;38:261-271.
FULL TEXT
|
ISI
| PUBMED
39. Weaver V, Sanchez C. Adverse drug reactions in a state psychiatric hospital. N C Med J. 1995;56:506-508.
PUBMED
40. Leonard LL, ed, Lacy CF, ed, Armstrong LL, ed, Goldman MP, ed. Drug Information Handbook for the Allied Health Professional. 8th ed. Hudson, Ohio: Lexi-Comp, Inc; 2000:860.
41. Bertilsson L, Dahl M. Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand Suppl. 1997;391:14-21.
PUBMED
42. Burchell B, Coughtrie M. Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation. Environ Health Perspect. 1997;105:739-747.
43. Hasler J. Pharmacogenetics of cytochromes P450. Mol Aspects Med. 1999;20:12-24, 25-137.
44. Ingelman-Sundberg M. The Gerhard Zbinden Memorial Lecture. Genetic polymorphism of drug metabolizing enzymes: implications for toxicity of drugs and other xenobiotics. Arch Toxicol Suppl. 1997;19:3-13.
PUBMED
45. Ingelman-Sundberg M. Functional consequences of polymorphism of xenobiotic metabolising enzymes. Toxicol Lett. 1998;102-103:155-160.
46. Iyer L. Inherited variations in drug-metabolizing enzymes: significance in clinical oncology. Mol Diagn. 1999;4:327-333.
FULL TEXT
|
ISI
| PUBMED
47. Marshall A. Laying the foundations for personalized medicines. Nat Biotechnol. 1997;15:954-957.
FULL TEXT
|
ISI
| PUBMED
48. Masimirembwa C, Hasler J. Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants. Brain Res Bull. 1997;44:561-571.
FULL TEXT
|
ISI
| PUBMED
49. McLeod H, Krynetski E, Relling M, Evans W. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia. 2000;14:567-572.
FULL TEXT
|
ISI
| PUBMED
50. Meyer U, Zanger U. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol. 1997;37:269-296.
FULL TEXT
|
ISI
| PUBMED
51. Miller MS, McCarver D, Bell D, Eaton D, Goldstein J. Genetic polymorphisms in human drug metabolic enzymes. Fundam Appl Toxicol. 1997;40:1-14.
FULL TEXT
|
ISI
| PUBMED
52. Nagata K, Yamazoe Y. Pharmacogenetics of sulfotransferase. Annu Rev Pharmacol Toxicol. 2000;40:159-176.
FULL TEXT
|
ISI
| PUBMED
53. Nebert D, Ingelman-Sundberg M, Daly A. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. Drug Metab Rev. 1999;31:467-487.
FULL TEXT
|
ISI
| PUBMED
54. Smith G, Stubbins M, Harries L, Wolf C. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica. 1998;28:1129-1165.
FULL TEXT
|
ISI
| PUBMED
55. Tanaka E. Update: genetic polymorphism of drug metabolizing enzymes in humans. J Clin Pharm Ther. 1999;24:323-329.
FULL TEXT
|
ISI
| PUBMED
56. van der Weide J, Steijns L. Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem. 1999;36:722-729.
57. Vermes A, Guchelaar H, Koopmans R. Individualization of cancer therapy based on cytochrome P450 polymorphism: a pharmacogenetic approach. Cancer Treat Rev. 1997;23:321-339.
FULL TEXT
|
ISI
| PUBMED
58. West WL, Knight EM, Pradhan S, Hinds TS. Interpatient variability: genetic predisposition and other genetic factors. J Clin Pharmacol. 1997;37:635-648
ABSTRACT
59. Yokoi T, Kamataki T. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes [in Japanese]. Nippon Yakurigaku Zasshi. 1998;112:5-14.
PUBMED
60. Ingelman-Sundberg M, Daly A, Oscarson M, Nebert D. Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles. Pharmacogenetics. 2000;10:91-93.
FULL TEXT
|
ISI
| PUBMED
61. American Health Formulary Service. AHFS Drug Information 2001. Bethesda, Md: American Society of Health System Pharmacists; 2001.
62. Top 200 brand-name drugs by retail sales in 2000. DrugTopics.com. March 19, 2001. Available at: http://dt.pdr.net/dt/index.htm. Accessed October 10, 2001.
63. Medical Economics Company. Physicians Desk Reference. 55th ed. Montvale, NJ: Medical Economics Co; 2000.
64. Hansten P, Horn J. Drug Interactions: Analysis and Management. St Louis, Mo: Facts and Comparisons—A Wolters Kluwer Co; 2000.
65. Drug Interactions. Micromedex Healthcare Series for Windows vol 107 [database on CD-ROM]. Greeenwood Village, Colo: Micromedex/Thomson Healthcare; 2001.
66. Wandel C, White J, Hall J, Stein C, Wood A, Wilkinson G. CYP3A4 activity in African American and European American men: population differences and functional effect of the CYP3A4*aB 5'-promoter region polymorphism. Clin Pharmacol Ther. 2000;68:82-91.
FULL TEXT
|
ISI
| PUBMED
67. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383-391.
FULL TEXT
|
ISI
| PUBMED
68. Wolf C, Smith G. Pharmacogenetics. Br Med Bull. 1999;55:366-386.
FREE FULL TEXT
69. Mancinelli L, Cronin M, Sadee W. Pharmacogenomics: the promise of personalized medicine. AAPS PharmSci. 2000;2:article 4. Available at: http://www.pharmsci.org. Accessibility verified October 10, 2001.
70. Phillips KA, Veenstra D, Sadee W. Implications of the genetics revolution for health services research: pharmacogenomics and improvements in drug therapy. Health Serv Res. 2000;35:1-12.
ISI
| PUBMED
71. Veenstra D, Higashi M, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. 2000;2:article 29. Available at: http://www.pharmsci.org. Accessibility verified October 10, 2001.
72. Holtzman N, Marteau T. Will genetics revolutionize medicine? N Engl J Med. 2000;343:141-144.
FREE FULL TEXT
73. Sadee W. Pharmacogenomics. BMJ. 1999;319:1-4.
FREE FULL TEXT
74. Norton RM. Pharmacogenomics and individualized drug therapy. Medscape Pharmacotherapy, 2001. Available at: http://www.medscape.com/Home/HumorLeisure/HumorLeisure.html. Accessibility verified October 10, 2001.
75. Krynetski E, Evans W. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase. Pharm Res. 1999;16:342-349.
FULL TEXT
|
ISI
| PUBMED
76. Ravdin P. Should HER2 status be routinely measured for all breast cancer patients? Semin Oncol. 1999;26:117-123.
ISI
| PUBMED
77. Chaix C, Holtzer C, Phillips KA, Durand-Zaleski I, Stansell J. HIV-1 drug resistance genotyping: a review of clinical and economic issues. Pharmacoeconomics. 2000;18:425-433.
FULL TEXT
|
ISI
| PUBMED
78. Scanlon C, Fibison W. Managing genetic information: implications for nursing practice. Washington, DC: American Nurses Association Publications; 1995:1-50.
79. Sadee W. Genomics and drugs: finding the optimal drug for the right patient. Pharm Res. 1998;15:959-963.
FULL TEXT
|
ISI
| PUBMED
80. Regalado A. Inventing the pharmacogenomics business. Am J Health Syst Pharm. 1999;56:40-50.
FREE FULL TEXT
81. Swartz K. The human genome and medical care in the new century. Inquiry. 2000;37:3-6.
FULL TEXT
|
ISI
| PUBMED
82. Austin M, Peyser P, Khoury M. The interface of genetics and public health: research and educational challenges. Annu Rev Public Health. 2000;21:81-99.
FULL TEXT
|
ISI
| PUBMED
83. Omenn G. Public health genetics: an emerging interdisciplinary field for the post-genomic era. Annu Rev Public Health. 2000;21:1-13.
FULL TEXT
|
ISI
| PUBMED
84. Khoury M, Burke W, Thomson E. Genetics and public health in the 21st century. New York, NY: Oxford University Press; 2000:639.
85. Weinstein M, Goldie S, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001;134:440-450.
FREE FULL TEXT
86. Schoonmaker M, Bernhardt B, Holtzman N. Factors influencing health insurers' decisions to cover new genetic technologies. Int J Technol Assess Health Care. 2000;16:178-189.
FULL TEXT
|
ISI
| PUBMED
87. Spear B. Pharmacogenomics: today, tomorrow, and beyond. Drug Benefit Trends. 1999;11:53-54.
88. Classen D, Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospital patients. JAMA. 1991;266:2847-2851.
FREE FULL TEXT
89. Bowman L, Carlstedt BC, Black CD. Incidence of adverse drug reactions in adult medical inpatients. Can J Hosp Pharm. 1994;47:209-216.
PUBMED
90. Aithal G, Day C, Kesteven P, Daly A. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353:717-719.
FULL TEXT
|
ISI
| PUBMED
91. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood. 2000;96:1816-1819.
FREE FULL TEXT
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED ARTICLE
November 14, 2001
JAMA. 2001;286(18):2337-2338.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Considerations in using anticoagulant therapy in special patient populations
Phillips et al.
Am J Health Syst Pharm 2008;65:S13-S21.
ABSTRACT
| FULL TEXT
Novel CYP2C9 Promoter Variants and Assessment of Their Impact on Gene Expression
Kramer et al.
Mol. Pharmacol. 2008;73:1751-1760.
ABSTRACT
| FULL TEXT
TPMT testing in rheumatology: any better than routine monitoring?
Payne et al.
Rheumatology (Oxford) 2007;46:727-729.
FULL TEXT
Identifying drugs needing pharmacogenetic monitoring in a Korean hospital
Kim et al.
Am J Health Syst Pharm 2007;64:166-175.
ABSTRACT
| FULL TEXT
Pharmacogenetics as Alien Science: Alzheimer's Disease, Core Sets and Expectations
Hedgecoe
Social Studies of Science 2006;36:723-752.
ABSTRACT
The Intersection Of Biotechnology And Pharmacogenomics: Health Policy Implications
Phillips
Health Aff (Millwood) 2006;25:1271-1280.
ABSTRACT
| FULL TEXT
Genetic testing in cancer therapeutics.
Ezzeldin and Diasio
Clin. Cancer Res. 2006;12:4137-4141.
FULL TEXT
Metabolism of Efavirenz and 8-Hydroxyefavirenz by P450 2B6 Leads to Inactivation by Two Distinct Mechanisms
Bumpus et al.
J. Pharmacol. Exp. Ther. 2006;318:345-351.
ABSTRACT
| FULL TEXT
Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine
McDowell et al.
BMJ 2006;332:1177-1181.
ABSTRACT
| FULL TEXT
Role of CYP2E1 Immunoglobulin G4 Subclass Antibodies and Complement in Pathogenesis of Idiosyncratic Drug-Induced Hepatitis
Njoku et al.
CVI 2006;13:258-265.
ABSTRACT
| FULL TEXT
In vitro and In vivo Clinical Pharmacology of Dimethyl Benzoylphenylurea, a Novel Oral Tubulin-Interactive Agent
Rudek et al.
Clin. Cancer Res. 2005;11:8503-8511.
ABSTRACT
| FULL TEXT
Pharmacogenetics/genomics and personalized medicine
Sadee and Dai
Hum Mol Genet 2005;14:R207-R214.
ABSTRACT
| FULL TEXT
Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy
Ingelman-Sundberg and Rodriguez-Antona
Phil Trans R Soc B 2005;360:1563-1570.
ABSTRACT
| FULL TEXT
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia
Rocha et al.
Blood 2005;105:4752-4758.
ABSTRACT
| FULL TEXT
Pharmacogenomics: Harbinger for the Era of Personalized Medicine?
Sadee
Mol. Interv. 2005;5:140-143.
FULL TEXT
Sequence variation in G-protein-coupled receptors: analysis of single nucleotide polymorphisms
Balasubramanian et al.
Nucleic Acids Res 2005;33:1710-1721.
ABSTRACT
| FULL TEXT
Genes and the Response to Drugs
Caraco
NEJM 2004;351:2867-2869.
FULL TEXT
Technology And The Boundaries Of The Hospital: Three Emerging Technologies
Goldsmith
Health Aff (Millwood) 2004;23:149-156.
ABSTRACT
| FULL TEXT
Criteria influencing the clinical uptake of pharmacogenomic strategies
Shah
BMJ 2004;328:1482-1486.
FULL TEXT
Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions
Bellosta et al.
Circulation 2004;109:III-50-III-57.
ABSTRACT
| FULL TEXT
The Clinical Relevance of Genomic Variation
Kansagra and List
JAMA 2004;291:1641-1641.
FULL TEXT
Racial Meanings and Scientific Methods: Changing Policies for NIH-Sponsored Publications Reporting Human Variation
Stevens
Journal of Health Politics, Policy and Law 2003;28:1033-1088.
ABSTRACT
Improving medication safety: the measurement conundrum and where to start
Classen and Metzger
Int J Qual Health Care 2003;15:i41-47.
ABSTRACT
| FULL TEXT
Polymorphisms and the Pocketbook: The Cost-Effectiveness of Cytochrome P450 2C19 Genotyping in the Eradication of Helicobacter pylori Infection Associated with Duodenal Ulcer
Lehmann et al.
J Clin Pharmacol 2003;43:1316-1323.
ABSTRACT
| FULL TEXT
A mouse-based strategy for cyclophosphamide pharmacogenomic discovery
Watters et al.
J. Appl. Physiol. 2003;95:1352-1360.
ABSTRACT
| FULL TEXT
Genetic Polymorphism of CYP1A2 in Ethiopians Affecting Induction and Expression: Characterization of Novel Haplotypes with Single-Nucleotide Polymorphisms in Intron 1
Aklillu et al.
Mol. Pharmacol. 2003;64:659-669.
ABSTRACT
| FULL TEXT
Drug-Induced Hepatotoxicity
Lee
NEJM 2003;349:474-485.
FULL TEXT
The Drugs Don't Work: Expectations and the Shaping of Pharmacogenetics
Hedgecoe and Martin
Social Studies of Science 2003;33:327-364.
ABSTRACT
Pharmacogenomics: marshalling the human genome to individualise drug therapy
Evans
Gut 2003;52:ii10-18.
ABSTRACT
| FULL TEXT
Pharmacogenomic can give children safer medicines
Impicciatore
Arch. Dis. Child. 2003;88:366-366.
FULL TEXT
Medication Safety: Moving From Illusion to Reality
Classen
JAMA 2003;289:1154-1156.
FULL TEXT
Cardiovascular Pharmacogenomics: Current Status, Future Prospects
Anderson et al.
J CARDIOVASC PHARMACOL THER 2003;8:71-83.
ABSTRACT
Single base extension (SBE) with proofreading polymerases and phosphorothioate primers: improved fidelity in single-substrate assays
Di Giusto and King
Nucleic Acids Res 2003;31:e7-e7.
ABSTRACT
| FULL TEXT
Genetics 101: detecting mutations in human genes
Sinclair
CMAJ 2002;167:275-279.
FULL TEXT
Pharmacogenetic Challenges For The Health Care System
Robertson et al.
Health Aff (Millwood) 2002;21:155-167.
ABSTRACT
| FULL TEXT
Cochrane Corner
Hachinski
Stroke 2002;33:1739-1739.
FULL TEXT
Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin Therapy
Higashi et al.
JAMA 2002;287:1690-1698.
ABSTRACT
| FULL TEXT
Chemokines and Transplant Immunobiology
Hancock
J. Am. Soc. Nephrol. 2002;13:821-824.
FULL TEXT
Genetics Moves Into the Medical Mainstream
Collins and Guttmacher
JAMA 2001;286:2322-2324.
FULL TEXT
|
